Sanford C. Bernstein Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) Stock

Insulet (NASDAQ:PODD) had its price target hoisted by equities researchers at Sanford C. Bernstein from $400.00 to $410.00 in a note issued to investors on Friday,MarketScreener reports. Sanford C. Bernstein’s price target suggests a potential upside of 28.20% from the stock’s previous close.

Other research analysts have also issued research reports about the stock. Rothschild & Co Redburn upped their price target on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Raymond James Financial boosted their price objective on Insulet from $360.00 to $366.00 and gave the stock an “outperform” rating in a report on Friday. Oppenheimer boosted their price target on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. Stifel Nicolaus assumed coverage on Insulet in a report on Tuesday, October 21st. They set a “buy” rating and a $370.00 target price for the company. Finally, The Goldman Sachs Group reduced their target price on shares of Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus target price of $370.76.

Insulet Stock Down 1.1%

PODD stock opened at $319.82 on Friday. Insulet has a twelve month low of $230.05 and a twelve month high of $353.50. The company has a market cap of $22.51 billion, a price-to-earnings ratio of 97.21, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The business has a 50 day moving average price of $325.06 and a two-hundred day moving average price of $309.40.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm’s revenue for the quarter was up 29.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts anticipate that Insulet will post 3.92 EPS for the current fiscal year.

Insider Activity at Insulet

In related news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.39% of the company’s stock.

Institutional Investors Weigh In On Insulet

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Larson Financial Group LLC raised its holdings in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 81 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in Insulet during the first quarter worth $26,000. SouthState Corp boosted its position in Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 76 shares during the last quarter. True Wealth Design LLC lifted its stake in Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 72 shares during the period. Finally, Kozak & Associates Inc. acquired a new stake in shares of Insulet in the 2nd quarter valued at about $32,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.